| EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection P Lampertico, K Agarwal, T Berg, M Buti, HLA Janssen, ... Journal of hepatology 67 (2), 370-398, 2017 | 4897 | 2017 |
| EASL clinical practice guidelines: management of chronic hepatitis B virus infection European Association For The Study Of The Liver Journal of hepatology 57 (1), 167-185, 2012 | 3295 | 2012 |
| Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection N Afdhal, S Zeuzem, P Kwo, M Chojkier, N Gitlin, M Puoti, ... New England Journal of Medicine 370 (20), 1889-1898, 2014 | 2160 | 2014 |
| Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study P Marcellin, E Gane, M Buti, N Afdhal, W Sievert, IM Jacobson, ... The Lancet 381 (9865), 468-475, 2013 | 2093 | 2013 |
| Genomewide association study of severe Covid-19 with respiratory failure Severe Covid-19 GWAS Group New England Journal of Medicine 383 (16), 1522-1534, 2020 | 1966 | 2020 |
| Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study D Razavi-Shearer, I Gamkrelidze, MH Nguyen, DS Chen, P Van Damme, ... The lancet Gastroenterology & hepatology 3 (6), 383-403, 2018 | 1582 | 2018 |
| Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B P Marcellin, EJ Heathcote, M Buti, E Gane, RA de Man, Z Krastev, ... New England Journal of Medicine 359 (23), 2442-2455, 2008 | 1511 | 2008 |
| Hepatitis C virus antibodies among risk groups in Spain JI Esteban, L Viladomiu, A Gonzalez, M Roget, J Genesca, R Esteban, ... The Lancet 334 (8658), 294-297, 1989 | 1224 | 1989 |
| Mapping the human genetic architecture of COVID-19 Writing group Writing group leaders Pathak Gita A. 6 Andrews Shea J. 7 Kanai ... Nature 600 (7889), 472-477, 2021 | 771 | 2021 |
| Efficacy of lamivudine in patients with hepatitis B e antigen–negative/hepatitis B virus DNA–positive (precore mutant) chronic hepatitis befficacy of lamivudine in patients … NC Tassopoulos, R Volpes, G Pastore, J Heathcote, M Buti, RD Goldin, ... Hepatology 29 (3), 889-896, 1999 | 766 | 1999 |
| Efficacy of 24 weeks treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia S Zeuzem, M Buti, P Ferenci, J Sperl, Y Horsmans, J Cianciara, E Ibranyi, ... Journal of hepatology 44 (1), 97-103, 2006 | 665 | 2006 |
| Three-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B EJ Heathcote, P Marcellin, M Buti, E Gane, A Robert, Z Krastev, ... Gastroenterology 140 (1), 132-143, 2011 | 660 | 2011 |
| Hepatitis C virus infection MP Manns, M Buti, ED Gane, JM Pawlotsky, H Razavi, N Terrault, ... Nature reviews Disease primers 3 (1), 1-19, 2017 | 631 | 2017 |
| A systematic review of hepatitis C virus epidemiology in Europe, Canada and Israel M Cornberg, HA Razavi, A Alberti, E Bernasconi, M Buti, C Cooper, ... Liver International 31, 30-60, 2011 | 594 | 2011 |
| The present and future disease burden of hepatitis C virus (HCV) infection with today's treatment paradigm H Razavi, I Waked, C Sarrazin, RP Myers, R Idilman, F Calinas, W Vogel, ... Journal of viral hepatitis 21, 34-59, 2014 | 567 | 2014 |
| Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): a randomised … M Manns, P Marcellin, F Poordad, ESA De Araujo, M Buti, Y Horsmans, ... The Lancet 384 (9941), 414-426, 2014 | 541 | 2014 |
| Ledipasvir and sofosbuvir plus ribavirin in patients with genotype 1 or 4 hepatitis C virus infection and advanced liver disease: a multicentre, open-label, randomised, phase 2 … M Manns, D Samuel, EJ Gane, D Mutimer, G McCaughan, M Buti, ... The Lancet Infectious Diseases 16 (6), 685-697, 2016 | 520 | 2016 |
| Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind … M Buti, E Gane, WK Seto, HLY Chan, WL Chuang, T Stepanova, AJ Hui, ... The lancet Gastroenterology & hepatology 1 (3), 196-206, 2016 | 507 | 2016 |
| PAGE-B predicts the risk of developing hepatocellular carcinoma in Caucasians with chronic hepatitis B on 5-year antiviral therapy G Papatheodoridis, G Dalekos, V Sypsa, C Yurdaydin, M Buti, J Goulis, ... Journal of hepatology 64 (4), 800-806, 2016 | 480 | 2016 |
| Tenofovir disoproxil fumarate (TDF), emtricitabine/TDF, and entecavir in patients with decompensated chronic hepatitis B liver disease YF Liaw, IS Sheen, CM Lee, US Akarca, GV Papatheodoridis, ... Hepatology 53 (1), 62-72, 2011 | 419 | 2011 |
Fabien ZoulimProfessor of Medicine, Lyon UniversityDirección de correo verificada de inserm.fr
